KFDA instructed for Gleevec to be properly administered.

Published: 2001-09-20 06:56:00

Updated: 2001-09-20 06:56:00

The KFDA instructed the medical, hospital and pharmacist associations to administer Gleevec, a therapeutic agent for a chronic myeloid leukemia according to the approved indications and efficacies, because its use recently exploited to other cancers, thus causing its abuse and misuse.

Gleevec...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK